Connecting communities to tackle cancer from many sides.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 33831376.
- Also identified by DOI 10.1016/j.cell.2021.03.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interdisciplinary work has played a key role in Dr. Elizabeth Eisenhauer's wide-ranging research contributions and leadership in cancer clinical trials, drug delivery, treatment standards, and research and prevention strategy. Cell editor Emma Yee talked with Dr. Eisenhauer, recipient of the 2021 Canada Gairdner Wightman Award, to learn more about the factors that influenced her work in cancer care and the lessons she learned along the way. This conversation is presented below, edited for clarity and length. Note the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) was renamed the Canadian Cancer Trials Group (CCTG) in 2016. In this interview, the two are used interchangeably.
Medical subject headings
- Neoplasms